Peptide Bio IndexEvidence first. Hype last.
⌕

MOTS-C Human Trials and Exercise Studies

Written by

in

Peptide Research Overviews
PBIPeptide Bio Index Editorial DeskSource-labeled research summary
Source-limited9 min readUpdated Sep 3, 2026
Jump to a section
  1. What MOTS‑c is and core mechanistic observations
  2. Human clinical and observational evidence (what has been reported)
  3. Exercise, skeletal muscle, and metabolism studies (cell and animal evidence)
  4. Mechanistic pathways relevant to exercise and muscle function
  5. Safety, regulatory context, and research gaps
  6. Reported study-design details from cited sources
  7. Limitations and research gaps
  8. Documentation checklist
  9. Related research supplies
  10. More MOTS-c research
  11. Sources and references

Disclosure: Peptide Bio Index is affiliated with SourcePoint Research and may earn from qualifying purchases or affiliate links.

This article summarizes published research and reported study designs. It is not medical advice, dosing guidance, or a personal-use recommendation.

Source-limited research note: The reviewed sources were incomplete, ambiguous, or insufficient for a normal article. This page labels missing details rather than guessing.

This deep dive summarizes reviewed evidence on MOTS-c (the 16–amino‑acid mitochondrial‑derived peptide) with emphasis on human clinical signals and exercise/skeletal muscle studies. The reviewed literature describes MOTS-c as a mitochondrial peptide that translocates to the nucleus and alters nuclear gene expression, with primary experimental effects demonstrated in cells and animal models for metabolic homeostasis and skeletal muscle function. Human data in the reviewed sources are limited and mostly observational; randomized human exercise trials or standardized clinical administration protocols are not reported in the reviewed sources.

What MOTS‑c is and core mechanistic observations

MOTS-c is a 16–amino‑acid peptide encoded in the mitochondrial 12S rRNA region; it has been reported to translocate to the nucleus in response to metabolic stress and to regulate nuclear gene expression, including genes with antioxidant response elements (AREs) and stress‑responsive transcription factors such as NRF2 (NFE2L2) in cell models. Experimental work also links MOTS-c action to metabolic regulators including AMPK and to improved glucose metabolism in skeletal muscle in preclinical studies. [S1] [S6] [S2]

Human clinical and observational evidence (what has been reported)

Reviewed clinical or patient‑sample observations include reports of reduced MOTS-c levels in serum and tumor tissues from ovarian cancer patients that were associated with prognosis, and a clinical finding that perioperative increases in serum MOTS-c within 24 hours after cardiopulmonary bypass (ΔMOTS-c) correlated with postoperative ARDS risk and added predictive discrimination in multivariate models (reported AUC=0.885). Older age–related declines in circulating MOTS-c have also been noted in review literature. Systematic reviews of peptides in sports medicine emphasize that rigorous human safety and efficacy data for MOTS-c are scarce in the literature reviewed here. [S3] [S5] [S1] [S8]

Exercise, skeletal muscle, and metabolism studies (cell and animal evidence)

Preclinical evidence identifies skeletal muscle as a principal target of MOTS-c: in mice, MOTS-c treatment prevented age‑dependent and high‑fat‑diet‑induced insulin resistance and diet‑induced obesity and improved muscle glucose metabolism; cell studies show nuclear translocation and gene regulation after metabolic stress. Separate mouse studies report that systemic MOTS-c administration prevented skeletal muscle atrophy and enhanced muscle glucose uptake, and a gestational diabetes mouse model reported daily MOTS-c administration during pregnancy improved insulin sensitivity and muscle glucose uptake in that disease model. The reviewed sources do not describe randomized human exercise intervention trials of MOTS-c, and reviews highlight the limited human safety/efficacy data available. [S2] [S6] [S7] [S4] [S8]

Mechanistic pathways relevant to exercise and muscle function

Mechanistic findings across reviewed studies include MOTS-c inhibition of the folate cycle and de novo purine biosynthesis tethering leading to AMPK activation, nuclear translocation with regulation of ARE‑containing genes and interaction with NRF2, and a reported direct interaction with and activation of CK2 that appears required for muscle effects in mice. Additional work in an ischemia–reperfusion context identified MOTS-c promoting nuclear translocation via MYH9 and activating antioxidant gene transcription, linking ROS‑CK2A‑MYH9 signaling to MOTS-c nuclear activity in endothelial cells. [S2] [S6] [S7] [S5]

Safety, regulatory context, and research gaps

Reviews emphasize a growing marketplace for peptides but note a lack of rigorous human safety data for MOTS-c in the reviewed literature and state that no effective clinical application method for MOTS-c has been established in clinical practice. Major gaps in the reviewed evidence include few controlled human interventional trials, sparse standardized dosing or administration protocols reported in human studies, and limited published human safety data. [S8] [S1]

Reported study-design details from cited sources

The following table summarizes protocol details reported in cited studies. These details are provided as literature context only and are not recommendations or instructions.

Source Study Type Model / Subject Amount Reported Route Reported Frequency Duration Notes
[S4] Journal Article (animal study) Mouse (gestational diabetes model: short-term high-fat diet + low‑dose streptozotocin) not reported in the reviewed source not reported in the reviewed source daily during pregnancy MOTS-c administration during pregnancy in this GDM mouse model significantly alleviated hyperglycemia, improved insulin sensitivity and glucose tolerance, reduced birth weight and offspring mortality, increased skeletal muscle insulin sensitivity and glucose uptake in vitro, and protected pancreatic β‑cells from STZ injury.
[S2] Journal Article (animal study) Mouse (age-dependent and high‑fat diet models) not reported in the reviewed source not reported in the reviewed source not reported in the reviewed source not reported in the reviewed source MOTS-c treatment in mice prevented age-dependent and high‑fat‑diet‑induced insulin resistance and diet-induced obesity and improved skeletal muscle glucose metabolism via AMPK activation mechanisms reported in the article.
[S7] Journal Article (animal study) Mouse (skeletal muscle atrophy models) not reported in the reviewed source not reported in the reviewed source not reported in the reviewed source not reported in the reviewed source Systemic MOTS-c administration to mice prevented skeletal muscle atrophy and enhanced muscle glucose uptake; effects were linked to direct binding and activation of CK2 and were modified by a naturally occurring human MOTS-c variant (K14Q) that showed reduced CK2 binding and functional effects.
[S5] Journal Article (animal model + clinical biomarker observations) Rat (lung ischemia–reperfusion injury) and clinical perioperative serum observations (CPB patients) not reported in the reviewed source not reported in the reviewed source not reported in the reviewed source not reported in the reviewed source In rat LIRI models, exogenous MOTS-c administration attenuated lung injury, reduced oxidative damage and inflammation, and improved survival; mechanistic data implicated ROS‑CK2A‑MYH9 signaling and activation of antioxidant gene transcription. Clinically, perioperative increases in serum MOTS-c within 24 h post‑CPB were reported to outperform traditional biomarkers for predicting ARDS incidence (multivariate models with ΔMOTS-c achieved reported AUC=0.885).
[S3] Journal Article (human tissue observations and in vivo experimental models) Human tissue and in vivo cancer models (ovarian cancer) not reported in the reviewed source not reported in the reviewed source not reported in the reviewed source not reported in the reviewed source MOTS-c levels were reduced in serum and tumor tissue from ovarian cancer patients and associated with poorer prognosis; exogenous MOTS-c inhibited proliferation, migration, invasion, and induced apoptosis in OC cells and produced marked anti‑tumor effects in vivo without reported systemic toxicity in that study.

Limitations and research gaps

  • Most mechanistic and efficacy data for MOTS-c in the reviewed sources are from cell and animal models; evidence directly from randomized human interventional trials is not reported in the reviewed sources.
  • Details commonly used for translating study protocols (specific administered amounts, explicit routes, precise frequency/duration) are frequently not reported in the reviewed excerpts; where not stated, the exact amount or route is 'not reported in the reviewed source.'
  • Observational human findings (serum level associations or perioperative biomarker changes) do not establish efficacy or safety for clinical use and are limited by observational design in the reviewed sources.
  • Safety and regulatory conclusions are constrained by the scarcity of rigorous human safety data in the reviewed literature.

Documentation checklist

  • Evidence base includes cell and animal experiments with limited human observational data
  • Mechanistic findings reported: AMPK activation, nuclear translocation, CK2 interaction, and ARE/NRF2-related gene regulation
  • Human interventional trials and standardized dosing/administration protocols not reported in the reviewed sources
  • When summarizing protocols, treat reported regimens as study design details, not clinical recommendations
  • Consider regulatory and safety context: reviews note scarce rigorous human safety data for MOTS-c
  • Laboratory sample inventory labels and tracking software
  • Ultra‑low‑temperature freezer storage racks and boxes
  • Biospecimen collection and storage forms
  • Surface and equipment disinfectant wipes (for lab surfaces)
  • Laboratory cold chain temperature logbooks

Research organization supplies: Common tools used for research documentation workflows may include lab notebooks, label makers, sample storage boxes, inventory stickers, and temperature log sheets.

Paid-link disclosure: Peptide Bio Index may earn a commission from qualifying purchases. As an Amazon Associate I earn from qualifying purchases.

Batch and inventory labeling

Phomemo M110 Label and Barcode Printer

A compact thermal label printer for inventory identifiers, storage-box labels, batch references, and document-folder organization.

View on Amazon (paid link)

Label-printer refill

Phomemo M110 White Replacement Labels

White 1.57 × 0.78 inch replacement labels for compatible Phomemo printers. Confirm printer and label-size compatibility before ordering.

View on Amazon (paid link)

Product listings, specifications, and availability can change. Review the current Amazon listing and manufacturer instructions before ordering. These links are for research organization and compatible surface/equipment-cleaning workflows, not personal-use guidance.

Research Supply Note: For research-use-only sourcing, review current SourcePoint Research inventory and batch documentation at SourcePointResearch.com. Peptide Bio Index is affiliated with SourcePoint Research.

More MOTS-c research

Sources and references

  1. [S1] Zheng Y, Wei Z, Wang T. MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation.. Frontiers in endocrinology. 2023. PMID: 36761202. DOI: 10.3389/fendo.2023.1120533
  2. [S2] Lee C, Zeng J, Drew BG, Sallam T, Martin-Montalvo A, Wan J. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance.. Cell metabolism. 2015. PMID: 25738459. DOI: 10.1016/j.cmet.2015.02.009
  3. [S3] Yin Y, Li Y, Ma B, Ren C, Zhao S, Li J. Mitochondrial-Derived Peptide MOTS-c Suppresses Ovarian Cancer Progression by Attenuating USP7-Mediated LARS1 Deubiquitination.. Advanced science (Weinheim, Baden-Wurttemberg, Germany). 2024. PMID: 39321430. DOI: 10.1002/advs.202405620
  4. [S4] Yin Y, Pan Y, He J, Zhong H, Wu Y, Ji C. The mitochondrial-derived peptide MOTS-c relieves hyperglycemia and insulin resistance in gestational diabetes mellitus.. Pharmacological research. 2022. PMID: 34798268. DOI: 10.1016/j.phrs.2021.105987
  5. [S5] Li X, Zhan F, Qiu G, Lu P, Shen Z, Qi Y. MOTS-c attenuates lung ischemia-reperfusion injury via MYH9-Dependent nuclear translocation and transcriptional activation of antioxidant genes.. Redox biology. 2025. PMID: 40403491. DOI: 10.1016/j.redox.2025.103681
  6. [S6] Kim KH, Son JM, Benayoun BA, Lee C. The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic Stress.. Cell metabolism. 2018. PMID: 29983246. DOI: 10.1016/j.cmet.2018.06.008
  7. [S7] Kumagai H, Kim SJ, Miller B, Zempo H, Tanisawa K, Natsume T. MOTS-c modulates skeletal muscle function by directly binding and activating CK2.. iScience. 2024. PMID: 39559755. DOI: 10.1016/j.isci.2024.111212
  8. [S8] Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.. Sports medicine (Auckland, N.Z.). 2026. PMID: 41966639. DOI: 10.1007/s40279-026-02437-0

Peptide Bio Index is affiliated with SourcePoint Research. Articles may link to SourcePointResearch.com and third-party affiliate products. As an Amazon Associate, Peptide Bio Index earns from qualifying purchases. Content is educational and research-literature focused only and is not medical advice, dosing guidance, or a personal-use recommendation.

More posts